Safety and efficacy of apatinib plus S-1 after failure of second-line or third-line chemotherapy in patients with advanced non-small cell lung cancer: A retrospective study

Trial Profile

Safety and efficacy of apatinib plus S-1 after failure of second-line or third-line chemotherapy in patients with advanced non-small cell lung cancer: A retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Apatinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 New trial record
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
    • 01 Jun 2017 Recruitment completed, according to results presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top